[8-K] Lyra Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Lyra Therapeutics filed an 8-K reporting it announced financial results for the quarter ended June 30, 2025. The filing states the company furnished a press release as Exhibit 99.1 and posted a corporate presentation on its website, furnished as Exhibit 99.2. Both exhibits are expressly described as "furnished, and not filed," and the company disclaims any obligation to update the presentation. The filing identifies Lyra's common stock as trading under the symbol LYRA on The Nasdaq Capital Market and indicates the company is an emerging growth company. The report is signed by CFO Jason Cavalier on August 12, 2025.

Positive

• Quarterly results announced for the period ended June 30, 2025, with a press release furnished as Exhibit 99.1
• Investor presentation posted on the company's website and furnished as Exhibit 99.2, increasing accessibility to investor materials
• Disclosure compliance: filing executed and signed by the CFO, meeting SEC procedural requirements

Negative

• No financial figures or tables are included in the 8-K text; investors must consult the furnished exhibits for numeric results
• Exhibits furnished, not filed, meaning they are not subject to Section 18 liability and are not incorporated by reference into other filings by this document
• Company disclaims any obligation to update the presentation, limiting follow-up clarifications within this filing

Insights

Financial Analyst

TL;DR: Routine earnings disclosure and investor materials furnished; no financial figures included in this 8-K.

The filing confirms Lyra released its quarterly results for the period ended June 30, 2025 via a press release (Exhibit 99.1) and provided an investor presentation (Exhibit 99.2). Both exhibits are furnished rather than filed, meaning the 8-K itself does not include audited financial statements or the detailed numbers investors would need to assess performance. For analysts, the next step is to review the referenced exhibits on the company website or in furnished exhibit filings to extract revenue, EPS, cash position, and guidance, none of which are present in this document.

Corporate Governance Expert

TL;DR: Disclosure practices follow standard SEC procedure; exhibits furnished to satisfy timely disclosure obligations.

The company used Item 2.02 to announce results and Item 7.01 to post an investor presentation, explicitly identifying the materials as furnished and not subject to Section 18 liabilities. The filing also states the company will not update Exhibit 99.2, which is a common disclaimer. The filing is signed by the CFO, fulfilling signature requirements. These actions reflect routine, compliant disclosure rather than a material corporate action.

false000132727300013272732025-08-122025-08-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

Lyra Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39273	84-1700838
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
480 Arsenal Way
Watertown, Massachusetts				02472
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 617 393-4600

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		LYRA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2025, Lyra Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.

Item 7.01 Regulation FD.

On August 12, 2025 the Company posted a corporate presentation on its website at www.lyratherapeutics.com that representatives of the Company may use from time to time in presentations or discussions with investors, analysts or other parties. A copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.2.

The information contained in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.2 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly provided by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following Exhibits 99.1 and 99.2 shall be deemed to be furnished, and not filed:

Exhibit No.		Description
99.1		Press Release issued on August 12, 2025
99.2		Corporate Presentation of Lyra Therapeutics, Inc. dated August 12, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Lyra Therapeutics, Inc.
Date:	August 12, 2025	By:	/s/ Jason Cavalier
			Jason Cavalier, Chief Financial Officer

FAQ

What did Lyra Therapeutics (LYRA) disclose in the 8-K filed August 12, 2025?

The company announced it disclosed financial results for the quarter ended June 30, 2025 via a press release (Exhibit 99.1) and posted an investor presentation (Exhibit 99.2).

Are the press release and presentation in the 8-K considered filed with the SEC?

No. The 8-K states both Exhibit 99.1 and Exhibit 99.2 are furnished, and not filed, and thus are not subject to Section 18 liabilities.

Where can investors find the corporate presentation mentioned in the 8-K?

The filing states the corporate presentation was posted on Lyra's website at www.lyratherapeutics.com and is furnished as Exhibit 99.2.

Does the 8-K include the financial numbers from the quarter?

No. The 8-K states the company announced results and furnished a press release, but the filing text does not include any financial figures or tables.

Who signed the 8-K for Lyra Therapeutics?

The report is signed by Jason Cavalier, Chief Financial Officer, dated August 12, 2025.